谢静文, 苏天德, 魏雨亭, 李歌, 吴建章, 黄丽丽. 抗氧化药物在心肌缺血再灌注损伤中的研究进展J. 药学学报, 2021,56(7): 1845-1855. doi: 10.16438/j.0513-4870.2020-1988
引用本文: 谢静文, 苏天德, 魏雨亭, 李歌, 吴建章, 黄丽丽. 抗氧化药物在心肌缺血再灌注损伤中的研究进展J. 药学学报, 2021,56(7): 1845-1855. doi: 10.16438/j.0513-4870.2020-1988
XIE Jing-wen, SU Tian-de, WEI Yu-ting, LI Ge, WU Jian-zhang, HUANG Li-li. Research progress of antioxidant drugs in myocardial ischemia-reperfusion injuryJ. Acta Pharmaceutica Sinica, 2021,56(7): 1845-1855. doi: 10.16438/j.0513-4870.2020-1988
Citation: XIE Jing-wen, SU Tian-de, WEI Yu-ting, LI Ge, WU Jian-zhang, HUANG Li-li. Research progress of antioxidant drugs in myocardial ischemia-reperfusion injuryJ. Acta Pharmaceutica Sinica, 2021,56(7): 1845-1855. doi: 10.16438/j.0513-4870.2020-1988

抗氧化药物在心肌缺血再灌注损伤中的研究进展

Research progress of antioxidant drugs in myocardial ischemia-reperfusion injury

  • 摘要: 心肌缺血再灌注损伤是心血管疾病研究中的难点之一,细胞中过多活性氧(reactive oxygen species,ROS)的积累是其主要致病原因。通过抗氧化药物降低ROS水平并保护心肌细胞是目前研究的热点。本文对近年来抗氧化药物在心肌缺血再灌注损伤中的相关研究进行了综述。

     

    Abstract: Myocardial ischemia-reperfusion injury (MIRI) is one of the most difficulties in the studies of cardiovascular diseases, and excessive reactive oxygen species (ROS) accumulation in cells is the main cause of it. Reducing ROS level by antioxidant drugs to protect cardiomyocytes is being the spotlight on MIRI treatment. In this review, the research progress of antioxidant drugs in myocardial ischemia-reperfusion injury in recent years was summarized.

     

/

返回文章
返回